Benzinga | Mar 18, 2021 08:10AM EDT

UroGen Pharma Q4 EPS $(1.38) Misses $(1.37) Estimate, Sales $7.97M Beat $7.57M Estimate

UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(1.38) per share which missed the analyst consensus estimate of $(1.37) by 0.73 percent. This is a 25.81 percent increase over losses of $(1.86) per share from the same period last year. The company reported quarterly sales of $7.97 million which beat the analyst consensus estimate of $7.57 million by 5.23 percent.